3,199 reports of this reaction
2.3% of all POMALIDOMIDE reports
#8 most reported adverse reaction
NEUTROPENIA is the #8 most commonly reported adverse reaction for POMALIDOMIDE, manufactured by Celgene Corporation. There are 3,199 FDA adverse event reports linking POMALIDOMIDE to NEUTROPENIA. This represents approximately 2.3% of all 136,988 adverse event reports for this drug.
POMALIDOMIDE has an overall safety score of 88 out of 100. Patients taking POMALIDOMIDE who experience neutropenia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
NEUTROPENIA is a less commonly reported adverse event for POMALIDOMIDE, but still significant enough to appear in the safety profile.
In addition to neutropenia, the following adverse reactions have been reported for POMALIDOMIDE:
The following drugs have also been linked to neutropenia in FDA adverse event reports:
NEUTROPENIA has been reported as an adverse event in 3,199 FDA reports for POMALIDOMIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
NEUTROPENIA accounts for approximately 2.3% of all adverse event reports for POMALIDOMIDE, making it a notable side effect.
If you experience neutropenia while taking POMALIDOMIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.